Daclizumab OverviewDaclizumab (trade name Zinbryta, by Biogen) is a therapeutic humanized monoclonal antibody used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells. It was formerly marketed under the trade name Zenapax to prevent acute rejection in people with kidney transplants along with cyclosporine and corticosteroids but marketing of the drug for that purpose was discontinued in 2009 due to la...
Read more Daclizumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Daclizumab
Recent Daclizumab Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 150mg/ml, 5mg/ml
- Vial: 25mg/vial
NDC Database Records for Daclizumab: (1 result)Sorted by National Drug Code
- 0074-0034 Zinbryta 150 mg/ml Subcutaneous Injection, Solution by Abbvie